3048-48-4

Usage

Uses

Used in Pharmaceutical Industry:
Benzothiazole, 4-methyl(7CI,8CI,9CI) is used as an intermediate in the synthesis of 4-Benzothiazoleacetic Acid (B200500) for the development of acyloxyalkyl and aspartyl amidooxyalkyl ketones. These compounds exhibit ICE-inhibiting activities, which are crucial in the pharmaceutical industry for the development of drugs targeting various diseases and conditions.

InChI:InChI=1/C8H7NS/c1-6-3-2-4-7-8(6)9-5-10-7/h2-5H,1H3

Upstream product

• 609-72-3 N,N-dimethyl-o-toluidine 
• 3507-47-9 4-methyl-benzothiazole-2-carboxylic acid 
• 127-19-5 N,N-dimethyl acetamide 
• 86749-03-3 6,6′-disulfanediylbis(2-methylaniline) 
• 1477-42-5 4-methyl-1,3-benzothiazol-2-amine 
• 124-38-9 carbon dioxide 
• 76462-17-4 2-methyl 6-mercapto aniline 
• 100817-89-8 N-(4-methylbenzothiazol-2-yl)acetamide 
• 6303-21-5 hypophosphorous acid 

Downstream Products

• 57527-89-6 1-(4-Methyl-2-benzothiazolyl)-ethanol 
• 3507-47-9 4-methyl-benzothiazole-2-carboxylic acid 
• 1448856-31-2 2-(phenylthio)-4-methylbenzo[d]thiazole 
• 936827-75-7 benzothiazole-4-methylamine 
• 63325-84-8 4-methyl-2-phenylbenzo[d]thiazole 
• 76462-17-4 2-methyl 6-mercapto aniline 
• 936827-73-5 4-bromomethylbenzothiazole 

Relevant academic research and scientific papers

Iron-catalyzed tandem oxidative coupling and acetal hydrolysis reaction to prepare formylated benzothiazoles and isoquinolines

The aldehyde group is one of the most versatile intermediates in synthetic chemistry, and the introduction of an aldehyde group into heteroarenes is important for the transformation of molecular structure. Herein, we achieved the direct formylation of benzothiazo/les and isoquinolines. The reaction features a novel iron-catalyzed Minisci-type oxidative coupling process using commercially available 1,3-dioxolane as a formylated reagent followed by acetal hydrolysis without a separation process. The reaction can be performed under exceedingly mild reaction conditions and exhibits broad functional group tolerance.

Novel SIRT 1 activator and medical use thereof

The present invention relates to a SIRT 1 activator and medical uses thereof. In the present invention, a novel SIRT 1 activator compound based on a benzo[d]thiazole skeleton, a crystalline form thereof, a hydrate thereof or a salt thereof is prepared, and effect on alleviating obesity, insulin resistance and dyslipidemia, alleviating fatty liver, preventing cell aging, preventing oxidative stress and extending of life of yeast. Therefore, the novel SIRT 1 activator compound having the above effects can be used for a pharmaceutical composition for therapeutic use for preventing or treating metabolic diseases including obesity, diabetes mellitus, dyslipidemia and the like and liver diseases including alcoholic or non-alcoholic fatty liver, fatty liver diseases and the like, and a health food composition for alleviating cell aging or prolonging the life span, and the like.COPYRIGHT KIPO 2018

Synthesis of benzothiazoles from 2-aminobenzenethiols in the presence of a reusable polythiazolium precatalyst under atmospheric pressure of carbon dioxide

Synthesis of benzothiazoles from 2-aminobenzenethiols and carbon dioxide was carried out using poly(3,4-dimethyl-5-vinylthiazolium) iodide as a precatalyst to in situ generation of NHCs by deprotonation. The reaction was successfully carried out under mild conditions (1 atm of CO2 and 60–70 °C) with a broad substrate scope and functional group tolerance. The precatalyst salt was recovered and reused for several times without any loss of activity.

N-Iodosuccinimide involved one-pot metal-free synthesis of 2-heteroaromatic benzothiazole compounds

A one-pot protocol for the synthesis of structurally diverse 2-hetarylbenzothiazoles via oxidative condensation of the sp3 C-H bond with benzothiazoles has been described. This process is metal free and operationally simple. A series of 2-hetarylbenzothiazoles were prepared in moderate to good yield under mild conditions.

ALFA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS

The invention provides alpha-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein a-mimetic compounds are used to treat cancer stem cells.

TBHP-mediated oxidative thiolation of an sp3 C-H bond adjacent to a nitrogen atom in an amide

The first example of molecular sieve-promoted TBHP-mediated direct oxidative thiolation of an sp3 C-H bond adjacent to a nitrogen atom with disulfides under metal-free conditions, which allows for preparation of numerous S,N-containing compounds, is presented. Moreover, diverse benzothiazoles and a fipronil analog can be synthesized through this strategy.

(3R)-3-Amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides and 3-amino-N-(4-aryltetrahydropyran-4-yl)butanamides were synthesized and evaluated as dipeptidyl peptidase IV (DPP-IV) inhibitors. Derivatives incorporating the 6-substituted benzothiazole group showed highly potent DPP-IV inhibitory activity. Oral administration of (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide (12u) reduced blood glucose excursion in an oral glucose tolerance test.

Antiviral dibenzothiazepinone derivatives

Compounds of formula (I) wherein n is 0, 1 or 2; and R1 and R2, which may be the same or different, each represent one or more ring substituent(s) selected from: hydrogen, hydroxy, halogen, cyano, nitro, C1-6 alkyl, C3-6 cycloalkyl or C1-6 alkoxy (where the alkyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from halogen atoms and hydroxyl groups); --NR4 R5 where R4 and R5, which may be the same or different, each represent hydrogen or C1-6 alkyl; --S(O)m R6, where m is 0, 1, 2 or 3 and R6 represents hydrogen, C1-6 alkyl or C3-6 cycloakyl; --SO2 NR4 R5 where R4 et R5 are each as defined above; phenyl, phenylC1-3 alkoxy or phenylC1-3 alkyl where the phenyl group may be optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, hydroxy, nitro, halogen and amino; and --CO2 H or --COR7 where R7 is C1-6 alkyl or C3-6 cycloalkyl; R3 represents hydrogen or C1-4 alkyl; and esters, salts and other physiologically functional derivatives thereof; show activity as antiviral agents, for example against HIV. Certain of the compounds are novel.